Heroin-assisted treatment for opioid dependence

Key points
- Heroin-assisted treatment has been found to be effective for people with severe opioid dependence who are not interested in or do poorly on methadone maintenance.
- Correspondence: Dr Christian Haasen, Centre for Interdisciplinary Addiction Research, Department of Psychiatry, University Medical Centre Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
- To study heroin-assisted treatment in people on methadone who continue intravenous heroin and in those who are heroin dependent but currently not in treatment.
- In an open-label multicentre randomised controlled trial, 1015 people with heroin dependence received a variable dose of injectable heroin (n=515) or oral methadone (n=500) for 12 months.
Heroin-assisted treatment has been found to be effective for people with severe opioid dependence who are not interested in or do poorly on methadone maintenance.
To study heroin-assisted treatment in people on methadone who continue intravenous heroin and in those who are heroin dependent but currently not in treatment.
In an open-label multicentre randomised controlled trial, 1015 people with heroin dependence received a variable dose of injectable heroin (n=515) or oral methadone (n=500) for 12 months. Two response criteria, improvement of physical and/or mental health and decrease in illicit drug use, were evaluated in an intent-to-treat analysis.
Retention was higher in the heroin (67.2%) than in the methadone group (40.0%) and the heroin group showed a significantly greater response on both primary outcome measures. More serious adverse events were found in the heroin group, and were mainly associated with intravenous use.
Conclusions Heroin-assisted treatment is more effective for people with opioid dependence who continue intravenous heroin while on methadone maintenance or who are not enrolled in treatment. Despite a higher risk, it should be considered for treatment resistance under medical supervision.
Christian Haasen, MD, Uwe Verthein, PhD and Peter Degkwitz, PhD
Centre for Interdisciplinary Addiction Research, University Medical Centre Eppendorf, Hamburg
Juergen Berger, PhD
Institute for Medical Biometrics and Epidemiology, University Medical Centre Eppendorf, Hamburg
Michael Krausz, MD and Dieter Naber, MD
Centre for Interdisciplinary Addiction Research, University Medical Centre, Eppendorf, Hamburg, Germany
Correspondence: Dr Christian Haasen, Centre for Interdisciplinary Addiction Research, Department of Psychiatry, University Medical Centre Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Email: [email protected]
The British Journal of Psychiatry (2007) 191: 55-62. doi: 10.1192/bjp.bp.106.026112
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Mental Health →
NewsBetter options for people with treatment-resistant schizophrenia
In real-world settings, patients with schizophrenia whose symptoms do not respond to standard antipsychotic medications have better outcomes if they are switched to clozapine instead of another standard antipsychotic.…
7 November 2015
NewsTeam-based treatment is better for first episode psychosis
New research shows that treating people with first episode psychosis with a team-based, coordinated specialty care approach produces better clinical and functional outcomes than typical community care. Investigators…
21 October 2015
NewsDiabetes medication could be used to treat alcohol dependence
A new study on mice and rats at Sahlgrenska Academy shows that a medication used for diabetes and obesity also could be a valuable tool for the treatment of alcohol dependence. Alcohol dependence causes morbidity as…







